ESG LifeSciences is a Swiss investment company specialising in medical innovation financing. We scope out and commercialise transformative technologies which have the power to improve patients’ lives and enhance access to healthcare and well-being.
ESG LifeSciences is a Swiss investment company specialising in medical innovation financing. We scope out and commercialise transformative technologies which have the power to improve patients’ lives and enhance access to healthcare and well-being.
We believe in the transformative power of technology to deliver medical impact at pace and scale.
We target investments at a relatively late stage compared to traditional equity investors. This reduces the risk, shortens the investment period, and crystalizes value.
We are not dependent on selling shares to provide return. We structure investments to fit each particular opportunity, thereby facilitating faster crystallisation of value.
We are not only providers of capital, but also involved in supporting our portfolio companies in strategic pipeline development.
ESG Life Sciences is owned by ESGTI AG: an investment company driven by investments based on ESG principles. ESGTI AG has a broad portfolio which tackles food security, healthcare solutions and climate change. We are happy to extend this vision to our personal goal: to facilitate novel healthcare solutions for diseases and the environment, to alleviate human suffering and sustain nature.
ESG Life Sciences is owned by ESGTI AG: an investment company driven by investments based on ESG principles. ESGTI AG has a broad portfolio which tackles food security, healthcare solutions and climate change. We are happy to extend this vision to our personal goal: to facilitate novel healthcare solutions for diseases and the environment, to alleviate human suffering and sustain nature.
ESG Life Sciences is owned by ESGTI AG: an investment company driven by investments based on ESG principles. ESGTI AG has a broad portfolio which tackles food security, healthcare solutions and climate change. We are happy to extend this vision to our personal goal: to facilitate novel healthcare solutions for diseases and the environment, to alleviate human suffering and sustain nature.
We specialise in scoping out and commercialising transformative technologies which have the power to improve patient well-being and access to healthcare and wellcare.
We specialise in scoping out and commercialising transformative technologies which have the power to improve patient well-being and access to healthcare and wellcare. Our current portfolio can be found below.
SynDermix is a Swiss holding company, with a diversified portfolio of assets in the MedTech, Pharma, BioTech and Cosmeceutical spaces. It’s focus is on advancing effective and safe treatments, addressing important unmet medical needs.
Énielle AG is a Swiss innovator of cosmeceutical, personal care and consumer health products. As a WellCare specialist its flagship product is a skin serum specially crafted with natural active ingredients, proven to help regenerate the skin on a cellular level.
Rhéon Medical specialises in the development of glaucoma drainage devices and has the mission to provide optimal surgical solutions for glaucoma, developing non-invasive solutions and enhancing personalised care.
BioEleSonic™ is a developer of innovative medical devices, with a technology platform based on Precisely Modulated Acoustic Energy (PMAE). The Company develops high-potential assets until clinical proof of concept and then enters into partnerships for further development and/or licensing.
A developer of a novel proprietary formulation for the sustained release of nitric oxide. Noxogen Therapeutics’ development targets treatment of a wide range of medical disorders due to its powerful anti-inflammatory, antimicrobial and vasoregulatory effects
TheraLect is a BioTech company which leverages the antimicrobial properties and healing activities of Lectins (protein) found in plants to treat human disease. Its’ technology platform, rooted in cutting-edge DNA technology, is a novel recombinant plant lectin giving epithelial healing.
WEBSITE COMING SOON
We invest in companies that have demonstrated promising data and a reasonable proof of concept via our due diligence processes. Investment goals and subsequent business support range from progressing product development to assisting with business expansion; consistently rooted in a carefully managed investment process.
As a healthcare investment company that stays abreast of new investment opportunities, we are conscious that people and knowledge are key to business excellence. In addition to the specialist knowledge rooted in our portfolio companies, we are supported by a group of prestigious research advisors and organizations.
We invest in companies that have demonstrated promising data and a reasonable proof of concept via our due diligence processes. Investment goals and subsequent business support range from progressing product development to assisting with business expansion; consistently rooted in a carefully managed investment process.
We invest in companies that have demonstrated promising data and a reasonable proof of concept via our due diligence processes. Investment goals and subsequent business support range from progressing product development to assisting with business expansion; consistently rooted in a carefully managed investment process.
As a healthcare investment company that stays abreast of new investment opportunities, we are conscious that people and knowledge are key to business excellence. In addition to the specialist knowledge rooted in our portfolio companies, we are supported by a group of prestigious research advisors and organizations.
© 2022 ESG LifeSciences AG. All rights reserved. ・ Legal Notice ・ Privacy Policy
© 2021 ESG LifeSciences AG. All rights reserved.
